Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma

Autor:	Steven Du, Dan Beverly Fu, Daniela A Bota, Xiao-Tang Kong
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	Bruton's tyrosine kinase inhibitor diffuse large B-cell lymphoma ibrutinib primary CNS lymphoma relapsed or refractory primary CNS lymphoma whole-brain radiation therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	CNS Oncology, Vol 13, Iss 1 (2024)
Druh dokumentu:	article
ISSN:	20450907 2045-0915 2045-0907
DOI:	10.1080/20450907.2024.2345579
Popis:	Background: Treatment for refractory or relapsed primary CNS lymphoma (r/r PCNSL) is challenging. Salvage whole-brain radiation therapy (WBRT) is an option but has a short duration of disease control, so additional treatment modalities are warranted. Case: A 75-year-old female with r/r PCNSL who had multiple progressions after multiple lines of treatment underwent salvage WBRT. The patient received ibrutinib, a Bruton's tyrosine kinase inhibitor, as maintenance therapy for 18 months following WBRT with the intention of increasing survival duration after salvage WBRT. She survived 81 months from diagnosis, including 57 months after completion of WBRT. Conclusion: This case presentation describes the experience of using ibrutinib as maintenance therapy in treating r/r PCNSL after salvage WBRT.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/6fcd878256e3438f9e1ab60ab76be183 Zobrazit plný text záznamu View record in DOAJ